Ardelyx Posts 73% IBSRELA Revenue Growth, Eyes $1B Milestone by 2029
Event summary
- IBSRELA revenue grew 73% in 2025 to $274.2M, with total revenues reaching $407.3M.
- XPHOZAH revenue was $103.6M in 2025, reflecting year-over-year growth in total dispenses.
- Ardelyx launched a Phase 3 trial for IBSRELA in chronic idiopathic constipation (CIC) and a development program for RDX10531, a next-generation NHE3 inhibitor.
- The company expects IBSRELA to achieve $1B in annual revenue by 2029.
- Ardelyx reported a net loss of $61.6M for 2025, compared to a net loss of $39.1M in 2024.
The big picture
Ardelyx's strong revenue growth in 2025, driven by IBSRELA, positions it as a key player in the biopharmaceutical sector. The company's strategic focus on expanding indications and developing new therapies aligns with broader industry trends toward innovative treatments for unmet medical needs. With a well-capitalized position and a clear pipeline strategy, Ardelyx aims to deliver sustained value for shareholders while navigating the competitive landscape of gastrointestinal and renal therapies.
What we're watching
- Revenue Trajectory
- Whether Ardelyx can sustain the 73% growth rate for IBSRELA and meet its $1B revenue target by 2029.
- Clinical Development
- The pace at which the Phase 3 trial for IBSRELA in CIC progresses and the potential FDA approval timeline.
- Pipeline Progress
- How the development of RDX10531 advances and its potential impact on Ardelyx's long-term portfolio.
Related topics